Skip to main content

Ascendis Pharma

Ascendis Pharma A/S is a Danish biopharmaceutical company focused on developing therapies for rare endocrine and metabolic diseases. The company utilizes its proprietary TransCon technology platform to design prodrug therapies that provide sustained release of parent parent-drug molecules. Principal revenues are generated through product sales of its approved endocrinology treatments alongside licensing agreements and collaborative milestone payments. Its core end markets include endocrinology clinics, specialized hospitals, and rare disease treatment centers globally. Ascendis Pharma holds a strong competitive position in the global biopharmaceutical sector through its innovative long-acting therapeutic delivery platform. The company is headquartered in Hellerup, Denmark, and its American Depositary Shares are listed on the Nasdaq Global Select Market.

10 of the funds FundTelligence covers report a position in Ascendis Pharma.

Legal name
ASCENDIS PHARMA A/S
Sector
Health Care
Country
Denmark
Funds holding it
10

Funds holding Ascendis Pharma

Showing the 8 largest of 10 funds holding it.

Loading...